A Combinatorial Chemotherapy Regimen Induces Mismatch Repair Deficiency

Major Finding: Exposure to cisplatin and temozolomide promotes adaptive mismatch repair inactivation and sensitizes tumors to immunotherapy.Concept: This combined regimen increases neoantigen expression and presentation as well as adaptive and innate immunity.Impact: These findings provide evidence that chemical induction of mismatch repair deficiency can be combined with immunotherapy for cancer treatment.